

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Hong Kong prospectus dated Wednesday, October 23, 2024 (the “**Prospectus**”) of BEIJING BIOSTAR PHARMACEUTICALS CO., LTD. 北京華昊中天生物醫藥股份有限公司 (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong.

In connection with the Global Offering, CCB International Capital Limited and China Securities (International) Corporate Finance Company Limited act as the Joint Sponsors, the Sponsor-Overall Coordinators and the Overall Coordinators.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the other Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Thursday, October 31, 2024.)



**Beijing Biostar Pharmaceuticals Co., Ltd.**  
**北京華昊中天生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

<b>Number of Offer Shares under the Global Offering</b>	<b>: 14,588,000 H Shares</b>
<b>Number of Hong Kong Offer Shares</b>	<b>: 1,750,600 H Shares (as adjusted after reallocation)</b>
<b>Number of International Offer Shares</b>	<b>: 12,837,400 H Shares (as adjusted after reallocation)</b>
<b>Maximum Offer Price</b>	<b>: HK\$22.0 per H Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars, subject to refund)</b>
<b>Nominal value</b>	<b>: RMB1.00 per Offer Share</b>
<b>Stock code</b>	<b>: 2563</b>

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,  
Joint Bookrunners and Joint Lead Managers*



*Joint Bookrunners and Joint Lead Managers*



*Joint Lead Manager*



BEIJING BIOSTAR PHARMACEUTICALS CO., LTD. / 北京華昊中天生物醫藥股份  
有限公司

ANNOUNCEMENT OF FINAL OFFER PRICE AND  
ALLOTMENT RESULTS

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 23 October 2024 (the “**Prospectus**”) issued by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”).

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

**SUMMARY**

**Company information**

<b>Stock code</b>	2563
<b>Stock short name</b>	BIOSTAR PHARM-B
<b>Dealings commencement date</b>	31 October 2024*

\*see note at the end of the announcement

**Price Information**

<b>Final Offer Price</b>	HK\$16.000
<b>Offer Price Range</b>	HK\$16.000 - HK\$22.000

**Offer Shares and Share Capital**

<b>Number of Offer Shares</b>	14,588,000
<b>Number of Offer Shares in Public Offer (after reallocation)</b>	1,750,600
<b>Number of offer shares in International Offer (after reallocation)</b>	12,837,400
<b>Number of issued shares upon Listing</b>	364,588,000

**Proceeds**

<b>Gross proceeds (Note)</b>	HK\$ 233.41 million
<b>Less: Estimated listing expenses payable based on Final Offer Price</b>	HK\$ (37.52) million
<b>Net proceeds</b>	HK\$ 195.89 million

Note: Gross proceeds refers to the amount to which the issuer is entitled to receive. For details of the use of proceeds, please refer to the Prospectus dated 23 October 2024.

## ALLOTMENT RESULTS DETAILS

### **PUBLIC OFFER**

<b>No. of valid applications</b>	7,175
<b>No. of successful applications</b>	1,971
<b>Subscription level</b>	21.45 times
<b>Claw-back triggered</b>	No
<b>No. of Offer Shares initially available under the Public Offer</b>	1,458,800
<b>No. of Offer Shares reallocated from the International Offer</b>	291,800
<b>Final no. of Offer Shares under the Public Offer (after reallocation)</b>	1,750,600
<b>% of Offer Shares under the Public Offer to the Global Offering</b>	12.00%

*Note: For details of the final allocation of shares to the Public Offer, investors can refer to [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) to perform a search by identification number or [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) for the full list of allottees.*

### **INTERNATIONAL OFFER**

<b>No. of placees</b>	109
<b>Subscription Level</b>	0.994 times
<b>No. of Offer Shares initially available under the International Offer</b>	13,129,200
<b>No. of Offer Shares reallocated to the Public Offer</b>	291,800
<b>Final no. of Offer Shares under the International Offer (after reallocation)</b>	12,837,400
<b>% of Offer Shares under the International Offer to the Global Offering</b>	88.00%

*The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, the Single Largest Group of Shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, the Single Largest Group of Shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

The places in the International Offer include the following:

**Cornerstone Investors**

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Existing shareholders or their close associates</i>
WEALTH STRATEGY HOLDING LIMITED	4,857,600	33.30%	2.24%	1.33%	No
NOVOTECH SG HOLDINGS PTE. LTD.	1,442,600	9.89%	0.67%	0.40%	No
Baheal Wellness Industry International Trading Limited	961,000	6.59%	0.44%	0.26%	No
Silkywater Absolute Return LPF	3,847,200	26.37%	1.78%	1.06%	No
Total	11,108,400	76.15%	5.13%	3.05%	

**LOCK-UP UNDERTAKINGS**

**Single Largest Group of Shareholders**

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Baygen QT Inc. <sup>Note</sup>	40,505,885 (including 20,252,943 H Shares)	9.35%	11.11%	30 October 2025
Zhuhai Jingrong / 珠海京蓉昊緣投資合夥企業 (有限合夥) Note	20,392,815 (including 8,157,126 H Shares)	3.76%	5.59%	30 October 2025
Zhuhai Huajin / 珠海華錦昊緣企業管理合夥企業 (有限合夥) Note	19,220,863 (including 7,688,345 H Shares)	3.55%	5.27%	30 October 2025
Zhuhai Huaxin / 珠海華欣昊緣商業管理合夥企業(有限合夥) Note	14,002,034 (including 5,600,814 H Shares)	2.58%	3.84%	30 October 2025

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Beijing Baygen / 北京北進緣科技有限公司 Note	419,561 (including 167,824 H Shares)	0.08%	0.12%	30 October 2025
Zhuhai Huarong / 珠海華蓉昊緣企業管理合夥企業(有限合夥) Note	5,000,724 (including 2,000,290 H Shares)	0.92%	1.37%	30 October 2025
Tang Li / 唐莉 <sup>Note</sup>	3,592,932 (including 1,437,173 H Shares)	0.66%	0.99%	30 October 2025
Subtotal	103,134,814 (including 45,304,515 H Shares)	20.90%	28.29%	

*The expiry date of the lock-up period shown in the table above in respect of the H Shares is pursuant to the PRC Company Law. The lock-up requirement under the PRC Company Law is longer than the lock-up period required of the Warranting Shareholders under the Hong Kong Undertaking Agreement as disclosed in the Prospectus.*

*Note:*

*Immediately upon completion of the Global Offering, Dr. Tang Li will directly hold approximately 0.99% issued share capital of our Company, whilst Baygen QT Inc., Beijing Baygen Technologies Ltd.\* (北京北進緣科技有限公司) (“**Beijing Baygen**”), Zhuhai Huaxin Haoyuan Business Management Partnership(Limited Partnership)\* (珠海華欣昊緣商業管理合夥企業(有限合夥)), (“**Zhuhai Huaxin**”), Zhuhai Huajin Haoyuan Enterprise Management Partnership (Limited Partnership)\* (珠海華錦昊緣企業管理合夥企業(有限合夥)), (“**Zhuhai Huajin**”), Zhuhai Huarong Haoyuan Enterprise Management Partnership (Limited Partnership)\* (珠海華蓉昊緣企業管理合夥企業(有限合夥)) (“**Zhuhai Huarong**”), and Zhuhai Jingrong Haoyuan Investment Partnership (Limited Partnership)\* (珠海京蓉昊緣投資合夥企業(有限合夥)) (“**Zhuhai Jingrong**”), all of which were controlled by Dr. Tang Li, will in aggregate hold approximately 27.30% of the issued share capital of the Company. Therefore, Dr. Tang Li, Dr. Qiu Rongguo (being spouse of Dr. Tang Li), Baygen QT Inc., Beijing Baygen, Zhuhai Huaxin, Zhuhai Huajin, Zhuhai Jingrong and Zhuhai Huarong, will be in aggregate entitled to exercise approximately 28.29% (slightly lower than 30%) of the voting rights in the Company, and will constitute a Single Largest Group of Shareholders after Listing.*

*Pre-IPO Investors (as defined in the “History and Corporate Structure” section of the Prospectus)*

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Shanghai Xinsheng / 上海馨升德源企業管理中心 (有限合夥)	34,798,296 (including 28,000,000 H Shares)	12.92%	9.54%	30 October 2025
SDIC VC / 國投 (上海) 科技成果轉化創業投資基金企業 (有限合夥)	29,426,685 (including 0 H Shares)	0	8.07%	30 October 2025
Shanghai Haidai / 上海海岱帛泰企業管理中心 (有限合夥)	24,475,926 (including 12,237,963 H Shares)	5.65%	6.71%	30 October 2025
Efung Ruihua / 倚鋒睿華 (棗莊) 創業投資中心 (有限合夥) and Efung XIV / 倚鋒十四期(棗莊)創業投資中心(有限合夥)	21,827,261 (including 21,827,261 H Shares)	10.07%	5.99%	30 October 2025
Beijing Chongde / 北京崇德弘信創業投資中心 (有限合夥)	15,529,256 (including 0 H Shares)	0	4.26%	30 October 2025
Matrix Partners China VI, L.P. and Matrix Partners China VI-A, L.P.	17,150,002 (including 17,150,002 H Shares)	7.91%	4.70%	30 October 2025
Lapam VC / 北京龍磐創業投資中心(有限合夥)	13,969,660 (including 13,969,660 H Shares)	6.45%	3.83%	30 October 2025
Shenzhen Dachen / 深圳市達晨創豐股權投資企業(有限合夥)	12,822,213 (including 12,822,213 H Shares)	5.92%	3.52%	30 October 2025



<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Qianhai Jiancheng / 深圳前海建成開元企業管理有限公司 and Jianchuang Zhongmin / 建創中民(昆山)創業投資企業(有限合夥) and Jinding Investment / 金鼎投資(天津)有限公司	5,456,804 (including 5,456,804 H Shares)	2.52%	1.50%	30 October 2025
Chengdu Bio-city / 成都生物城一號股權投資基金合夥企業(有限合夥)	2,338,630 (including 2,338,630 H Shares)	1.08%	0.64%	30 October 2025
Foshan Hongtao / 佛山弘陶同選股權投資合夥企業(有限合夥)	2,079,392 (including 1,039,696 H Shares)	0.48%	0.57%	30 October 2025
Foshan Zhiyao VC / 佛山市智藥壹號創業投資合夥企業(有限合夥)	2,026,814 (including 2,026,814 H Shares)	0.94%	0.56%	30 October 2025
Sichuan Xintongde / 四川新同德大數據產業創業投資合夥企業(有限合夥)	1,911,698 (including 955,849 H Shares)	0.44%	0.52%	30 October 2025
Xiamen Feiyu / 廈門斐昱螢創實業投資合夥企業(有限合夥)	1,559,087 (including 1,559,087 H Shares)	0.72%	0.43%	30 October 2025



<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Chengdu VC / 成都創新風險投資有限公司 and Chengdu Jingrong / 成都菁融創業投資有限公司 and Chengdu Chengchuang / 成都成創智聯科技合夥企業(有限合夥)	4,460,618 (including 0 H Shares)	0	1.23%	30 October 2025
Langma 34 / 朗瑪三十四號 (深圳) 創業投資中心 (有限合夥) and Langma 32 / 朗瑪三十二號 (深圳) 創業投資中心 (有限合夥) and Langma 26 / 朗瑪二十六號 (深圳) 創業投資中心 (有限合夥)	2,683,089 (including 2,683,089 H Shares)	1.24%	0.73%	30 October 2025
Jinjiang Guangzi / 晉江光資創科壹號股權投資合夥企業(有限合夥)	779,543 (including 779,543 H Shares)	0.36%	0.21%	30 October 2025
Shenzhen Zhongju / 深圳中聚匯信投資中心(有限合夥)	670,767 (including 670,767 H Shares)	0.31%	0.18%	30 October 2025
Zhang Haiyan / 張海燕	11,118,115 (including 11,118,115 H Shares)	5.13%	3.05%	30 October 2025
Betta Pharmaceuticals Co., Ltd. / 貝達藥業股份有限公司	11,118,045 (including 0 H Shares)	0	3.05%	30 October 2025

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Zhongling VC / 北京中嶺燕園創業投資中心(有限合夥)	6,670,829 (including 3,335,414 H Shares)	1.54%	1.83%	30 October 2025
Gaoke Xinjun / 南京高科新浚成長一期股權投資合夥企業(有限合夥)	6,372,316 (including 3,186,158 H Shares)	1.47%	1.75%	30 October 2025
Jiaxing Xingkong / 嘉興星空瑰琦股權投資合夥企業(有限合夥) and Zhuhai Xingkong / 珠海星空瑤光投資合夥企業(有限合夥)	6,706,525 (including 6,706,525 H Shares)	3.09%	1.84%	30 October 2025
Tianjin Tianchuang / 天津天創湧鑫企業管理合夥企業(有限合夥)	3,897,726 (including 1,948,863 H Shares)	0.90%	1.07%	30 October 2025
Ningbo Jiusheng / 寧波梅山保稅港區久生投資合夥企業(有限合夥)	3,897,716 (including 3,897,716 H Shares)	1.80%	1.07%	30 October 2025
Ningbo Qirui / 寧波梅山保稅港區祺睿股權投資中心(有限合夥)	3,118,173 (including 3,118,173 H Shares)	1.44%	0.86%	30 October 2025
Subtotal	246,865,186 (including 156,828,342 H Shares)	72.39%	67.71%	

*The expiry date of the lock-up period shown in the table above is pursuant to the applicable PRC laws as disclosed in the Prospectus.*

**Cornerstone Investors**

<b>Name</b>	<b>Number of shares held in the Company subject to lock-up undertakings upon listing</b>	<b>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</b>	<b>% of shareholding in the Company subject to lock-up undertakings upon listing</b>	<b>Last day subject to the lock-up undertakings</b>
Novotech SG Holdings Pte. Ltd.	1,442,600 (including 1,442,600 H Shares)	0.67%	0.40%	30 April 2025
Baheal Wellness Industry International Trading Limited / 百洋健康產業國際商貿有限公司	961,000 <sup>Note</sup> (including 961,000 H Shares)	0.44%	0.26%	30 April 2025
SilkyWater Absolute Return LPF	3,847,200 (including 3,847,200 H Shares)	1.78%	1.06%	30 April 2025
Wealth Strategy Holding Limited / 富策控股有限公司	4,857,600 (including 4,857,600 H Shares)	2.24%	1.33%	30 April 2025
Subtotal	11,108,400 (including 11,108,400 H Shares)	5.13%	3.05%	

*In accordance with the respective Cornerstone Investment Agreements, the required lock-up ends on April 30, 2025. The Cornerstone Investors will cease to be prohibited from disposing of or transferring Shares subscribed for pursuant to the relevant Cornerstone Investment Agreements after the indicated date.*

*Note:*

*The number of Shares actually allocated to Baheal Wellness Industry International Trading Limited (百洋健康產業國際商貿有限公司) was 961,000 Shares, which is slightly lower than the 961,800 Shares as disclosed in the Prospectus. The decrease was due to fluctuations in exchange rates and based on arm's length negotiations among the relevant parties.*

***PLACEE CONCENTRATION ANALYSIS***

<b>Placees</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of Shares held upon Listing</b>	<b>% of total issued share capital upon Listing</b>
Top 1	4,857,600	37.84%	33.30%	4,857,600	1.33%
Top 5	12,811,200	99.80%	87.82%	12,811,200	3.51%
Top 10	12,815,600	99.83%	87.85%	12,815,600	3.52%
Top 25	12,820,600	99.87%	87.88%	12,820,600	3.52%

*Notes*

*\* Ranking of placees is based on the number of H Shares allotted to the placees.*

### ***H SHAREHOLDERS CONCENTRATION ANALYSIS***

<b>H Shareholders*</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>% of total issued H Shares capital upon Listing</b>	<b>Number of Shares held upon Listing</b>
Top 1	0	0.00%	0.00%	45,304,515	20.90%	103,134,814
Top 5	0	0.00%	0.00%	126,251,438	58.26%	190,880,033
Top 10	0	0.00%	0.00%	174,593,058	80.56%	251,459,616
Top 25	12,811,200	99.80%	87.82%	212,537,898	98.07%	298,914,588

*Notes*

\* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

### ***SHAREHOLDER CONCENTRATION ANALYSIS***

<b>Shareholders</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>Number of Shares held upon Listing</b>	<b>% of total issued share capital upon Listing</b>
Top 1	0	0.00%	0.00%	45,304,515	103,134,814	28.29%
Top 5	0	0.00%	0.00%	107,369,739	213,662,982	58.60%
Top 10	0	0.00%	0.00%	162,429,729	284,252,228	77.97%
Top 25	8,704,800	67.81%	59.67%	206,872,411	353,783,705	97.04%

*Notes*

\* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

## BASIS OF ALLOTMENT UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
<b>POOL A</b>			
200	2,900	129 out of 2,900 to receive 200 Shares	4.45%
400	1,006	89 out of 1,006 to receive 200 Shares	4.42%
600	356	47 out of 356 to receive 200 Shares	4.40%
800	182	32 out of 182 to receive 200 Shares	4.40%
1,000	440	94 out of 440 to receive 200 Shares	4.27%
1,200	102	26 out of 102 to receive 200 Shares	4.25%
1,400	69	20 out of 69 to receive 200 Shares	4.14%
1,600	72	23 out of 72 to receive 200 Shares	3.99%
1,800	81	29 out of 81 to receive 200 Shares	3.98%
2,000	569	225 out of 569 to receive 200 Shares	3.95%
3,000	196	116 out of 196 to receive 200 Shares	3.95%
4,000	276	217 out of 276 to receive 200 Shares	3.93%
5,000	119	117 out of 119 to receive 200 Shares	3.93%
6,000	91	200 Shares plus 16 out of 91 to receive additional 200 Shares	3.92%
7,000	33	200 Shares plus 12 out of 33 to receive additional 200 Shares	3.90%
8,000	45	200 Shares plus 24 out of 45 to receive additional 200 Shares	3.83%
9,000	26	200 Shares plus 18 out of 26 to receive additional 200 Shares	3.76%
10,000	268	200 Shares plus 236 out of 268 to receive additional 200 Shares	3.76%
20,000	154	600 Shares plus 117 out of 154 to receive additional 200 Shares	3.76%
30,000	45	1,000 Shares plus 26 out of 45 to receive additional 200 Shares	3.72%
40,000	33	1,400 Shares plus 14 out of 33 to receive additional 200 Shares	3.71%
50,000	30	1,800 Shares plus 8 out of 30 to receive additional 200 Shares	3.71%
60,000	14	2,200 Shares plus 2 out of 14 to receive additional 200 Shares	3.71%
70,000	4	2,600 Shares	3.71%
80,000	6	2,800 Shares plus 4 out of 6 to receive additional 200 Shares	3.67%
90,000	4	3,200 Shares plus 2 out of 4 to receive additional 200 Shares	3.67%
100,000	13	3,600 Shares plus 3 out of 13 to receive additional 200 Shares	3.65%
150,000	6	5,400 Shares plus 2 out of 6 to receive additional 200 Shares	3.64%
200,000	9	7,200 Shares plus 4 out of 9 to receive additional 200 Shares	3.64%
	<u>7,149</u>	<b>Total number of Pool A successful applicants: 1,945</b>	
<b>POOL B</b>			
250,000	13	26,200 Shares plus 6 out of 13 to receive additional 200 Shares	10.52%
300,000	7	31,400 Shares plus 2 out of 7 to receive additional 200 Shares	10.49%
400,000	1	41,800 Shares	10.45%
450,000	1	47,000 Shares	10.44%
500,000	1	52,200 Shares	10.44%
550,000	3	57,400 Shares	10.44%
	<u>26</u>	<b>Total number of Pool B successful applicants: 26</b>	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

## **COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

## **OTHERS/ADDITIONAL INFORMATION**

### **Reallocation**

As the International Offering is not fully subscribed and the Hong Kong Public Offering is fully subscribed or oversubscribed, the reallocation procedure as disclosed in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus has been applied.

The number of Offer Shares initially available under the Hong Kong Public Offering is 1,458,800 Shares, representing 10% of the total number of Offer Shares initially available under the Global Offering. As a result of such reallocation, the final number of Offer Shares under the Hong Kong Public Offering and the International Offering is adjusted to 1,750,600 Shares and 12,837,400 Shares, representing 12% and 88% of the total number of Offer Shares available under the Global Offering, respectively.



## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 23 October 2024 issued by Beijing Biostar Pharmaceuticals Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

*Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on 31 October 2024).*

## **PUBLIC FLOAT**

Immediately after completion of the Global Offering and conversion of the Unlisted Shares into H Shares, (i) 149,589,081 Shares, representing 41.03% of the total issued Shares will be held in the public hands, satisfying the minimum percentage requirement under Rule 8.08(1) of the Listing Rules; (ii) based on the Offer Price of HK\$16.00 per Share, the Company will have a market capitalization of at least HK\$375 million held by the public at the time of the Listing as required under Rule 18A.07 of the Listing Rules; (iii) the three largest public Shareholders will not hold more than 50% of the Shares held in the public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

The Directors confirm that immediately after the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company; and (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company.

## **COMMENCEMENT OF DEALINGS**

The Share certificates will only become valid evidence of title at 8:00 a.m. on Thursday, 31 October 2024 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for Termination” has not been exercised. Investors who trade the Shares on the basis of publicly available allocation details prior to the receipt of Share certificates or prior to the Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Thursday, 31 October 2024 (Hong Kong time), it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Thursday, 31 October 2024 (Hong Kong time). The Shares will be traded in board lots of 200 H Shares each, and the stock code of the Shares will be 2563.

By order of the Board  
**Beijing Biostar Pharmaceuticals Co., Ltd.**  
北京華昊中天生物醫藥股份有限公司  
**Dr. Tang Li**  
*Chairperson and Executive Director*

Hong Kong, 30 October 2024

*As at the date of this announcement, the directors of the Company are: (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Mr. Zhu Pai as non-executive Directors, and (iii) Dr. Meng Songdong, Ms. Qi Jingyao and Mr. Ran Dong as independent non-executive Directors.*